Contemporary management of prosthetic valve endocarditis: Principals and future outlook

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 5, 2015, Pages 501-510

  O'Connor, Cormac T ^a   Kiernan, Thomas J ^a,b  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^b UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

infective endocarditis; management; prosthetic valve endocarditis; review; valve

Indexed keywords

AMPHOTERICIN B; CEFEPIME; FLUCLOXACILLIN; GENTAMICIN; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AORTA VALVE REPLACEMENT; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONCURRENT INFECTION; ENTEROCOCCAL INFECTION; FUNGAL ENDOCARDITIS; HEALTHCARE ASSOCIATED INFECTION; HEART VALVE PROSTHESIS; HUMAN; INFECTION RATE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PROSTHETIC VALVE ENDOCARDITIS; SCINTIGRAPHY; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; ENDOCARDITIS; MICROBIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROSTHESIS-RELATED INFECTIONS;

ANTI-INFECTIVE AGENTS; ENDOCARDITIS; HEART VALVE PROSTHESIS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROSTHESIS-RELATED INFECTIONS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84928606836     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1035648     Document Type: Article

References (50)

1. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004;350:1422-9
2. Habib G, Thuny F, Avierinos JF. Prosthetic valve endocarditis: current approach and therapeutic options. Prog Cardiovasc Dis 2008;50:274-81
3. Tleyjeh IM, Abdel-Latif A, Rahbi H, et al. A systematic review of population-based studies of infective endocarditis. Chest 2007;132:1025-35
4. Habib G, Hoen B, Tornos P, et al. The task force on the prevention, diagnosis, and treatment of infective endocarditis of the European Society of Cardiology (ESC) Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). Eur Heart J 2009;30: 2369-413
5. Calderwood SB, Swinski LA, Waternaux CM, et al. Risk factors for the development of prosthetic valve endocarditis. Circulation 1985;72:31
6. Agnihotri AK, McGiffin DC, Galbraith AJ, et al. The prevalence of infective endocarditis after aortic valve replacement. J Thorac Cardiovasc Surg 1995;110:1708
7. Ivert TS, Dismukes WE, Cobbs CG, et al. Prosthetic valve endocarditis. Circulation 1984;69:223
8. Moreillon P, Que YA. Infective endocarditis. Lancet 2004;363:139-49
9. Rivas P, Alonso J, Moya J, et al. The impact of hospital-acquired infections on the microbial etiology and prognosis of late-onset prosthetic valve endocarditis. Chest 2005;128:764
10. Hill EE, Herregods MC, Vanderschueren S, et al. Management of prosthetic valve infective endocarditis. Am J Cardiol 2008;101:1174
11. Lee JH, Burner JD, Fealey ME, et al. Prosthetic valve endocarditis: Clinicopathological correlates in 122 surgical specimens from 116 patients (1985-2004). Cardiovasc Pathol 2011;20:26
12. Brennan JM, Edwards FH, Zhao Y, et al. Long-term safety and effectiveness of mechanical versus biologic aortic valve prostheses in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. Circulation 2013;127:1647
13. Wang A, Athan E, Pappas PA, et al. Contemporary Clinical Profile and Outcome of Prosthetic Valve Endocarditis. JAMA 2007;297(12):1354-61
14. Arvay A, Lengyel M. Incidence and risk factors of prosthetic valve endocarditis. Eur J Cardiothorac Surg 1988;2:340
15. Grover FL, Cohen DJ, Oprian C, et al. Determinants of the occurrence of and survival from prosthetic valve endocarditis. Experience of the Veterans Affairs Cooperative Study on Valvular Heart Disease. J Thorac Cardiovasc Surg 1994;108:207
16. Habib G, Derumeaux G, Avierinos JF, et al. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol 1999;33: 2023-9
17. Roe MT, Abramson MA, Li J, et al. Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the duke criteria. Am Heart J 2000;139:945
18. Lamas CC, Eykyn SJ. Suggested modifications to the Duke criteria for the clinical diagnosis of native valve and prosthetic valve endocarditis: analysis of 118 pathologically proven cases. Clin Infect Dis 1997;25:713-19
19. Vieira ML, Grinberg M, Pomerantzeff PM, et al. Repeated echocardiographic examinations of patients with suspected infective endocarditis. Heart 2004;90:1020
20. Saby L, Laas O, Habib G, et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol 2013;61:2374-82
21. Hyafil F, Rouzet F, Lepage L, et al. Role of radiolabelled leucocyte scintigraphy in patients with a suspicion of prosthetic valve endocarditis and inconclusive echocardiography. Eur Heart J Cardiovasc Imaging 2013;14:586-94
22. Rouzet F, Chequer R, Benali K, et al. Respective performance of 18F-FDG PET and radiolabeled leukocyte scintigraphy for the diagnosis of prosthetic valve endocarditis. J Nucl Med 2014;55:1980-5
23. Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med 1996;335:407-16
24. San Roman JA, Lopez J, Vilacosta I, et al. Prognostic stratification of patients with left-sided endocarditis determined at admission. Am J Med 2007;120:369 e1-7
25. Baddour LM, Wilson WR, Bayer AS, et al. Diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111:e394-434
26. Tornos P, Iung B, Permanyer-Miralda G, et al. Infective endocarditis in Europe: lessons from the Euro heart survey. Heart 2005;91:571-5
27. Keyser DL, Biller J, Coffman TT, et al. Neurologic complications of late prosthetic valve endocarditis. Stroke 1990;21:472
28. Thuny F, Avierinos JF, Tribouilloy C, et al. Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study. Eur Heart J 2007;28: 1155-61
29. Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001;32:50-62
30. Lalani T, Chu VH, Park LP, et al. In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med 2013; 173(16):1495
31. Lockhart PB, Brennan MT, Thornhill M, et al. Poor oral hygiene as a risk factor for infective endocarditis-related bacteremia. J Am Dent Assoc 2009;140(10):1238-44
32. Bargagli AM, Hickman M, Davoli M, et al. Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health 2006;16:198
33. Hogevik H, Olaison L, Anderson R, et al. Epidemiological aspects of infective endocarditis in an urban population: a five year prospective study. Medicine 1995;74: 324-39
34. Miro JM, del Rio A, Mestres CA. Infective endocarditis in intravenous drug abusers and HIV-1 infected patients. Infect Dis Clin N Am 2002;16:273-95
35. Mathew J, Addai T, Anand A, et al. Clinical features, site of involvement, bacteriologic findings, and outcome of infective endocarditis in intravenous drug users. Arch Intern Med 1995;155(15): 1641-8
36. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002;13(Suppl 1):S37-40
37. Glickman SW, Krubert C, Koppenhaver J, et al. Increased rate of central venous catheterization procedures in community EDs. Am J Emerg Med 2010;28(2):208-12
38. Nemes S, Gordon M, Rogmark C, et al. Projections of total hip replacement in Sweden from 2013 to 2030. Acta Orthop 2014;85(3):238-43
39. Selton-Suty C, Hoen B, Grentzinger A, et al. Clinical and bacteriological characteristics of infective endocarditis in the elderly. Heart 1997;77:260-3
40. Department of Economic and Social Affairs Population Division, United Nations World Population Aging: 1950-2050 Sales No. E.02.XIII.3. ISBN 92-1-051092-5
41. Di Salvo G, Thuny F, Rosenberg V, et al. Endocarditis in the elderly: clinical, echocardiographic, and prognostic features. Eur Heart J 2003;24:1576-83
42. Durante-Mangoni E, Bradley S, Selton-Suty C, et al. Current features of infective endocarditis in elderly patients: results of the international collaboration on endocarditis prospective cohort study. Arch Intern Med 2008;168:2095-103
43. Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005;293:3012-21
44. Wilson LE, Thomas DL, Astemborski J, et al. Prospective study of infective-endocarditis among injection drug users. J Infect Dis 2002;185:1761-6
45. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals. Clin Infect Dis 2004;39: 309-17
46. Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010;23(1):99-139
47. Twele L, Moyen E, Zhang K, et al. Methicillin-resistant Staphylococcus aureus endocarditis and de novo development of daptomycin resistance during therapy. Can J Infect Dis Med Microbiol 2010; 21(2):89-93
48. Mendes RE, Moet GJ, Janechek MJ, et al. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010;54: 2704-6
49. Nace H, Lorber B. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J Antimicrob Chemother 2010;65:1315-16
50. Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate staphylococcus aureus pacemaker lead infective endocarditis with telavancin antimicrob. Agents Chemother 2010;54(12): 5376-8